


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1099 of 1628 nlation vs. old formulation

Page 126 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T₄ Values) (Safety Population)

Subject ID/Random Number: ?



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.1.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL
INFORMATION

1099/1628

M

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T₄ Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1101 of 1628 nulation vs. old formulation

Page 128 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL
INFORMATION

1101/1628

M
0

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T₄ Values) (Safety Population)

Subject ID/Random Number: 104



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T₄ Values) (Safety Population)

Subject ID/Random Number:



Q: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01


**Levothyroxine
EMR 200125-001**

Bioequiv EMR200125-001 Page 1105 of 1628 nlation vs. old formulation

Page 132 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T₄ Values) (Safety Population)

Subject ID/Random Number: 150



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



0:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas


11DEC2014 00:01

**Levothyroxine
EMR 200125-001**

Bioequiv EMR200125-001 Page 1109 of 1628 alation vs. old formulation

Page 136 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)
Subject ID/Random Number: 1



④ Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL
INFORMATION

1109/1628

M


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1110 of 1628 nulation vs. old formulation

Page 137 of 216
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T₄ Values) (Safety Population)

Subject ID/Random Number:



€:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL
INFORMATION

1110/1628

M


**Levothyroxine
EMR 200125-001**

Bioequiv EMR200125-001 Page 1111 of 1628 nulation vs. old formulation

Page 138 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: :



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL
INFORMATION

1111/1628

M

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGures/FIGure
15.4.2.10.sas

11DEC2014 00:01

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T₄ Values) (Safety Population)

Subject ID/Random Number: J



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TPL programs/Figure
15.4.2.10.sas

11DEC2014 00:01

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figure
15.4.2.10.sas

11DEC2014 00:01


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1115 of 1628 nlation vs. old formulation

Page 142 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babc8085bb46 v1.0


CONFIDENTIAL
INFORMATION

1115/1628

WV

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: :



⑥:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.10.sas

11DEC2014 00:01


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1117 of 1628 nlation vs. old formulation

Page 144 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T₄ Values) (Safety Population)

Subject ID/Random Number:



0:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL
INFORMATION

1117/1628

M

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T₄ Values) (Safety Population)

Subject ID/Random Number: 1...111



©:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T₄ Values) (Safety Population)

Subject ID/Random Number: _____



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01


**Levothyroxine
EMR 200125-001**

Bioequiv EMR200125-001 Page 1120 of 1628 nulation vs. old formulation

Page 147 of 216
Confidential

Merci Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



0:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL
INFORMATION

1120/1628

M

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.3.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.3.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas


11DEC2014 00:01

Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1123 of 1628 uation vs. old formulation

Page 150 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T₄ Values) (Safety Population)
Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.3.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL
INFORMATION

1123/1628

M


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1124 of 1628 nlation vs. old formulation

Page 151 of 216
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



0: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL
INFORMATION

1124/1628


M

Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1125 of 1628 alation vs. old formulation

Page 152 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)
Subject ID/Random Number: J



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURE
15.4.2.10.sas

11DEC2014_00:01

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1127 of 1628 alation vs. old formulation

Page 154 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1 100



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.1.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.10.sas

11DEC2014 00:01

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: :




€:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1130 of 1628 nulation vs. old formulation



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL
INFORMATION

1130/1628

M

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01


**Levothyroxine
EMR 200125-001**

Bioequiv EMR200125-001 Page 1132 of 1628 uation vs. old formulation

Page 159 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T₄ Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.1.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.3.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T₄ Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



⑥:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1139 of 1628 alation vs. old formulation

Page 166 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T₄ Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figure
15.4.2.10.sas

11DEC2014 00:01


**Levothyroxine
EMR 200125-001**

Bioequiv EMR200125-001 Page 1141 of 1628 uation vs. old formulation

Page 168 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL
INFORMATION

1141/1628

AM

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:




⑥:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:




0:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T₄ Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01


**Levothyroxine
EMR 200125-001**

Bioequiv EMR200125-001 Page 1147 of 1628 alation vs. old formulation

Page 174 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.0.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL
INFORMATION

1147/1628

M

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:




⑥:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T₄ Values) (Safety Population)

Subject ID/Random Number: 1149



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Levothyroxine
EMR 200125-001


Bioequiv EMR200125-001 Page 1150 of 1628 alation vs. old formulation

Merck Serono
EMR 200125-001

Page 177 of 216
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



0: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL_programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL
INFORMATION

1150/1628

M

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



④ Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.10.sas

11DEC2014 00:01

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:




Q: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: :




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T₄ Values) (Safety Population)

Subject ID/Random Number:




④ Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figure
15.4.2.10.sas

11DEC2014 00:01

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: .




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:




④ Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.3.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: :



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figure
15.4.2.10.sas

11DEC2014 00:01


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1161 of 1628 olation vs. old formulation

Page 188 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL
INFORMATION

1161/1628

W


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1162 of 1628 alation vs. old formulation

Page 189 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.3.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



⑥Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figure
15.4.2.10.sas

11DEC2014 00:01

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1




⑥:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TEL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: :



€:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01


**Levothyroxine
EMR 200125-001**

Bioequiv EMR200125-001 Page 1170 of 1628 alation vs. old formulation

Page 197 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



⑥:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL
INFORMATION

1170/1628

M

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T₄ Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1173 of 1628 alation vs. old formulation

Page 200 of 216
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T₄ Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL
INFORMATION

1173/1628

M


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1174 of 1628 alation vs. old formulation

Page 201 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T₄ Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL
INFORMATION

1174/1628

M

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: :



⑥: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Levothyroxine
EMR 200125-001


Bioequiv EMR200125-001 Page 1176 of 1628 uation vs. old formulation

Merck Serono
EMR 200125-001

Page 203 of 216
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL
INFORMATION

1176/1628

M

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:




⑥Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figure
15.4.2.10.sas

11DEC2014 00:01

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T₄ Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



0: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

**Levothyroxine
EMR 200125-001**


Bioequiv EMR200125-001 Page 1182 of 1628 nlation vs. old formulation

Page 209 of 216
Confidential

Merck Serono
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL
INFORMATION

1182/1628

M

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: .




0: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:




⑥:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T₄ Values) (Safety Population)

Subject ID/Random Number: ..



①: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.3.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figure
15.4.2.10.sas

11DEC2014 00:01

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T₄ Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figure
15.4.2.10.sas

11DEC2014 00:01


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1189 of 1628 elation vs. old formulation

Page 216 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



⑥:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL
INFORMATION

1189/1628



Merck Serono
EMR 200125-001
Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T₃ Values)
(Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population;

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.11.sas

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL
INFORMATION


11DEC2014 00:01

1190/1628

M

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:



€:Subjects excluded from PK Population;

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.


Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.11.sas

Merck Serono
EMR 200125-001
Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.11.sas

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL
INFORMATION


11DEC2014 00:01

1192/1628

M

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.11.sas


**Levothyroxine
EMR 200125-001**

Bioequiv EMR200125-001 Page 1194 of 1628 uation vs. old formulation

Page 5 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.11.sas

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL
INFORMATION

11DEC2014 00:01
1194/1628 M


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1195 of 1628 uation vs. old formulation

Page 6 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.11.sas

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL
INFORMATION

11DEC2014 00:01
1195/1628

M


**Levothyroxine
EMR 200125-001**

Bioequiv EMR200125-001 Page 1196 of 1628 nlation vs. old formulation

Page 7 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T₃ Values)
(Safety Population)

Subject ID/Random Number:



⑥:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.11.sas

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL
INFORMATION

11DEC2014 00:01
1196/1628

M

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population;

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Table 16.1.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/main/TFL programs/FIGURES/FIGURE
15.4.2.11.sas

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL
INFORMATION

11DEC2014 00:01
1197/1628

M

Merck Serono
EMR 200125-001
Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T₃ Values)
(Safety Population)

Subject ID/Random Number:




€:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.11.sas

Merck Serono
EMR 200125-001
Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Page 10 of 216
Confidential

Subject ID/Random Number: 101



@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.11.sas


**Levothyroxine
EMR 200125-001**

Bioequiv EMR200125-001 Page 1200 of 1628 nulation vs. old formulation

Page 11 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population;

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.11.sas

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL
INFORMATION

11DEC2014 00:01
1200/1628

M